Currently, PD-1/PD-L1 pathway inhibitors have been tested for efficacy in a variety of tumor types, including ovarian, breast, bladder, colorectal, follicular lymphoma, gastric cancer and diffuse large B cell lymphoma [37–43]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.